14.45 -0.19 (-1.30%)
Pre-Market: 8:29AM EDT
|Bid||14.40 x 300|
|Ask||15.08 x 200|
|Day's Range||14.38 - 15.06|
|52 Week Range||6.41 - 17.40|
|PE Ratio (TTM)||N/A|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||N/A|
UniQure (QURE) is a leading company in the field of gene therapy. It has a focused pipeline of innovative gene therapies developed both internally and through collaboration for cardiovascular diseases. It has established clinical proof of concept for its lead indication, hemophilia B, and has achieved preclinical proof of concept in Huntington’s disease.
Voyager Therapeutics (VYGR) is a clinical-stage gene therapy company with a focus on developing treatments for severe neurological diseases. It focuses on those neurological diseases for which an adeno-associated virus (or AAV) gene therapy can reduce the symptoms experienced by patients. Of the 13 analysts covering Voyager Therapeutics in April 2018, five have given the stock “strong buy” ratings, five have given it “buy” ratings, and three have given it “hold” ratings.
The last time we checked in with Joseph Edelman, the founder, chief executive and portfolio manager of Perceptive Advisors and its hedge fund, Perceptive Life Sciences, he was buying stocks ahead of the new year. Edelman famously oversaw a 4% gain in 2016 as the biotech sector tumbled 20%. What stocks are Edelman, and his chief investment officer, Adam Stone, buying now?
The number of biotech stocks posting gains outstripped those recording losses for the week. Notable among the gainers for the week were Odonate Therapeutics Inc (NASDAQ: ODT ) — which reported its financial ...
Athenex and Amicus Therapeutics are a few noticeable companies with a strong future outlook. The market’s optimistic sentiment towards these stocks indicates a level of confidence in the future outlookRead More...
From acquisitions and equipment purchases to stock buybacks, firms are rapidly recalibrating their business plans in the wake of the corporate-tax overhaul. Specialty drugmaker Amicus Therapeutics, for ...
Why invest in a stock whose growth outlook that lags behind the market? Investors looking for companies with extraordinary future prospects in terms of profitability and returns should look atRead More...
Categories: ETFs Yahoo FinanceClick here to see latest analysis ETFs with exposure to Amicus Therapeutics, Inc. Here are 5 ETFs with the largest exposure to FOLD-US. Comparing the performance and risk of Amicus Therapeutics, Inc. with the ETFs that have exposure to it gives us some ETF choices that could give us similar returns with lower volatility. Ticker ... Read more (Read more...)
Individual investors like stocks with a high growth potential. These companies have a strong outlook that can bring a significant upside to your portfolio, regardless of market cyclicality. Analysing theRead More...
Amicus Therapeutics Inc (NASDAQ:FOLD), a biotechnology company based in United States, saw a decent share price growth in the teens level on the NasdaqGM over the last few months. WithRead More...
On a per-share basis, the Cranbury, New Jersey-based company said it had a loss of 69 cents. Losses, adjusted for one-time gains and costs, came to 41 cents per share. The results missed Wall Street expectations. ...
Amicus Therapeutics, Inc. (FOLD) is seeing favorable earnings estimate revision activity as of late, which is generally a precursor to an earnings beat.
Categories: ETFs Yahoo FinanceGet full CapitalCube analysis *Disclaimer : This is as of previous day’s closing price. Technical Indicators Below is a quick look at 5 technical indicators for Amicus Therapeutics, Inc.. More studies are available on the Technical Chart. Indicator Signal Closing Price above/below 50 Day Moving Average Bullish Closing Price above/below 200 Day Moving Average Bullish ... Read more (Read more...)
Sarepta Therapeutics and Amicus Therapeutics are tackling the unmet need for new treatments for rare conditions, and that could put them in position to generate market-beating returns.